Associated Papers
Rac1 selectively binds a specific lamellipodin isoform via a noncanonical helical interface.
Gao T et al.
The Journal of Biological Chemistry, 2026
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
Tumor-derived RAC1A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.
Cai M et al.
Science Advances, 2025
Intra-clustering analysis reveals tissue-specific mutational patterns.
Choudalakis S et al.
Computer Methods and Programs in Biomedicine, 2025
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.
Berg T et al.
Neoplasia (new York, N.y.), 2025
RAC1-Amplified and RAC1-A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept Study.
Chan HHY et al.
Cancers, 2025
Hallmarks of a genomically distinct subclass of head and neck cancer.
Muijlwijk T et al.
Nature Communications, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Tumor-derived RHOA mutants interact with effectors in the GDP-bound state.
Lin Y et al.
Nature Communications, 2024
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC et al.
Oncogene, 2024
Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior.
Gupta S et al.
The Journal of Pathology, 2024
Molecular dynamics simulation of RAC1 protein and its de novo variants related to developmental disorders.
Rani N et al.
Journal of Biomolecular Structure & Dynamics, 2024
Clinical profiling of MRD48 and functional characterization of two novel pathogenic RAC1 variants.
Priolo M et al.
European Journal of Human Genetics : Ejhg, 2023
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC et al.
Biorxiv : the Preprint Server for Biology, 2023
High frequency of PIK3CA and TERT promoter mutations in fibromatosis-like spindle cell carcinomas.
Zhong S et al.
Journal of Clinical Pathology, 2022
RHO GTPases: from new partners to complex immune syndromes.
El Masri R et al.
Nature Reviews. Immunology, 2021
Comprehensive characterization of protein-protein interactions perturbed by disease mutations.
Cheng F et al.
Nature Genetics, 2021
Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas.
Cui Y et al.
Plos One, 2021
RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC et al.
Trends in Cancer, 2020
Molecular therapeutics for anaplastic thyroid cancer.
Pozdeyev N et al.
Seminars in Cancer Biology, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic.
Casado-Medrano V et al.
Biochemical Society Transactions, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Pozdeyev N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
The Rac GTPase in Cancer: From Old Concepts to New Paradigms.
Kazanietz MG et al.
Cancer Research, 2017
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR et al.
Genome Medicine, 2017
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.
Gao J et al.
Genome Medicine, 2017
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
Chang MT et al.
Nature Biotechnology, 2016
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.
Wu G et al.
Nature Genetics, 2014